Bacil Pharma logo

Bacil Pharma financials and balance sheet

BSE: 524516Pharmaceuticals & BiotechnologySmall Cap

Last close ₹19.98down ₹0.46 (2.25%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹20.44.

52-week range of traded prices to 23 Oct 2026
₹10.65Low, 26 Aug 2026₹61.80High, 10 Apr 2026
Market cap
₹29 Cr3,172nd largest listed
P/E
Earlier quarters restated in the year
P/B
1.1
Dividend yield
Nonein the last 12 months
ROCE
−0.7%
Debt to equity
0.00
Volume, BSE
5,940

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Bacil Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹0.27 Cr, year to Mar 2018A loss in 8 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue0.0
  2. Employee costs0.0
  3. Other expenses−0.2
  4. Operating profit−0.2
  5. Depreciation0.0
  6. Other income+1.2
  7. One-off items0.0
  8. Finance costs0.0
  9. Profit before tax1.0
  10. Tax+0.6
  11. Net profit1.6

What the company owns

  • Plant, investments and other assets₹26 Cr
  • Receivables₹1 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹25 Cr
  • Other liabilities₹3 Cr
  • Owed to suppliers₹0 Cr

Profit and loss

Standalone, ₹ crore, years to March.Bacil Pharma quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 28 MayMar 2020Filed 5 AugMar 2021Filed 8 JulMar 2022Filed 15 JunMar 2023Filed 16 MayMar 2024Filed 20 JunMar 2025Filed 24 JunMar 2026Filed 22 May
Revenue from operations0.170.270.000.000.000.000.000.000.000.00
––0.430.450.313.910.210.190.250.25
Materials and goods bought––0.000.000.000.000.000.000.000.00
Employee costs––0.080.090.050.060.090.100.140.05
Other expenses––0.350.360.263.850.130.090.110.20
Operating profit before depreciation––−0.43−0.45−0.31−3.91−0.21−0.19−0.25−0.25
Depreciation and amortisation0.000.010.010.010.000.000.000.000.000.00
Operating profit after depreciation––−0.44−0.46−0.31−3.92−0.22−0.19−0.25−0.25
Other income0.170.270.090.140.070.060.110.130.661.24
Finance costs––0.000.000.000.000.000.000.000.00
Profit before one-off items and tax0.00−0.06−0.34−0.32−0.24−3.86−0.10−0.060.410.99
One-off items–−3.700.000.000.000.000.000.000.000.00
Profit before tax0.00−3.75−0.34−0.32−0.24−3.86−0.10−0.060.410.99
–0.000.000.000.000.000.000.000.00−0.57
Net profit0.00−3.75−0.34−0.32−0.24−3.86−0.10−0.060.401.56
Other comprehensive income––0.02−0.210.243.69−0.020.170.00−2.17
Total comprehensive income––−0.33−0.520.00−0.17−0.130.110.40−0.62
Net margin−1.2%−1,368.6%––––––––
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2017 and Mar 2018: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given.
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations0.270.16––0.461.06–––
–––––––––
Materials and goods bought0.230.14–––––––
Depreciation and amortisation–––––0.000.010.000.00
Other income0.050.010.030.040.060.010.060.080.06
Profit before tax0.00−0.04−0.02−0.020.05−0.02−0.11−0.03−0.07
Tax0.000.00––0.010.00–––
Net profit0.00−0.04−0.02−0.020.05−0.02−0.11−0.03−0.07
Net margin0.0%−22.8%––9.8%−2.2%–––
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2019Filed 28 MayMar 2020Filed 5 AugMar 2021Filed 8 JulMar 2022Filed 15 JunMar 2023Filed 16 MayMar 2024Filed 20 JunMar 2025Filed 24 JunMar 2026Filed 22 MaySep 2026Half yearFiled 14 Oct
1.91.41.41.21.11.225.424.825.3
Share capital6.56.56.56.56.56.514.014.014.0
Reserves−4.6−5.1−5.1−5.3−5.4−5.311.510.811.3
Borrowings0.10.20.20.00.00.10.20.00.0
2.62.72.70.00.00.10.22.60.0
0.00.00.00.00.00.00.00.00.1
4.64.14.11.31.11.325.627.425.3
1.53.83.80.80.71.322.725.60.5
0.60.30.30.50.40.12.91.824.8
Net debt−0.4−0.1−0.1−0.5−0.40.1−2.7−0.6−22.7
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Filed 8 JulMar 2022Filed 15 JunMar 2023Filed 16 MayMar 2024Filed 20 JunMar 2025Filed 24 JunMar 2026Filed 22 MaySep 2026Half yearFiled 14 Oct
−0.40−4.01−0.150.000.401.66−2.25
−0.40−4.01−0.150.000.431.66−2.25
−0.030.05−0.010.080.021.24−2.47
Receivables0.000.000.000.000.00−1.180.07
Payables−0.020.00−0.010.000.000.020.05
Other working capital0.000.050.000.080.022.40−2.59
Capital spending0.000.000.000.000.000.000.00
Free cash flow−0.40−4.01−0.150.000.401.66−2.25
0.533.81−0.120.080.34−3.381.62
−0.070.330.06−0.062.08−0.620.36
Dividends paid0.000.000.000.000.000.000.00
Shares bought back0.000.000.000.000.000.620.00
Shares issued0.000.000.000.00–0.000.36
Net change in cash0.060.13−0.200.012.82−2.34−0.27
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020. Shares issued is left blank for the year to Mar 2025: the cash-flow statement states money raised on equity instruments other than shares, and with no share capital on record before the period nothing shows whether shares were issued for it, so the figure is not given.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Filed 28 MayMar 2020Filed 5 AugMar 2021Filed 8 JulMar 2022Filed 15 JunMar 2023Filed 16 MayMar 2024Filed 20 JunMar 2025Filed 24 JunMar 2026Filed 22 May
Earnings per share–−₹6.37−₹0.58−₹0.54−₹0.41−₹6.55−₹0.17−₹0.10–₹1.11
Diluted earnings per share–−₹6.37−₹0.58−₹0.54−₹0.41−₹6.55−₹0.17−₹0.10–₹1.11
Book value per share––₹3.24₹2.35₹2.36₹2.08₹1.87₹2.06₹43.18₹17.76
Shareholder yield––––0.0%0.0%0.0%0.0%–0.9%
Market cap at the year end (₹ crore)4.22.0–1.01.83.43.28.625.068.5
Earnings per share is left blank for the year to Mar 2025: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period. Shareholder yield is left blank for the year to Mar 2025: the cash-flow statement states money raised on equity instruments other than shares, and with no share capital on record before the period nothing shows whether shares were issued for it, so the figure is not given.

Ratios

Standalone, years to March.Bacil Pharma PE ratio and valuation

RatioMar 2018Mar 2019Filed 28 MayMar 2020Filed 5 AugMar 2021Filed 8 JulMar 2022Filed 15 JunMar 2023Filed 16 MayMar 2024Filed 20 JunMar 2025Filed 24 JunMar 2026Filed 22 May
Revenue growth61.2%−100.0%–––––––
Net profit growth––––––––284.8%
Return on capital employed––−29.5%−20.0%−311.5%−19.3%−14.4%−1.0%−1.0%
Cash conversion–––––––99.2%106.9%
Debt to equity––0.120.130.030.020.080.010.00
Asset turnover–––0.000.000.000.000.000.00
Assets per rupee of net worth–––2.952.051.031.061.011.05
Sales per rupee of plant–0.000.000.000.000.000.00––
Capital spending to depreciation–––0.000.000.000.000.00–
Plant being built, % of plant in use–0.0%0.0%––0.0%0.0%––
Return on equity, asset turnover and assets per rupee of net worth are left blank for the years to Mar 2019 and Mar 2020: a tenth or more of the assets on the balance sheet it is worked from are held for sale or for a demerger, so it would mix the business being kept with the part that is leaving. Change in return on equity, from the net margin, from asset turnover and from borrowing are left blank for the years to Mar 2019, Mar 2020 and Mar 2021: a tenth or more of the assets on the balance sheet it is worked from are held for sale or for a demerger, so it would mix the business being kept with the part that is leaving. Debt to equity, receivable days, inventory days, payable days, cash conversion cycle, days, return on capital employed and working capital days are left blank for the year to Mar 2019: a tenth or more of the assets on the balance sheet it is worked from are held for sale or for a demerger, so it would mix the business being kept with the part that is leaving. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
5.9%
Measure5 years3 years
Return on capital employed, average−69.5%−5.5%
Asset turnover, average0.000.00
Debt to equity, average0.030.03

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−2.102.061.66
Cash from investing0.73−2.97−3.38
Cash from financing1.791.40−0.62
Capital spending0.000.000.00
Dividends paid0.000.000.00
Shares bought back0.620.620.62
Shares issued for cash––0.00
Borrowings raised0.000.000.00
Borrowings repaid1.130.740.00

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Altman Z-scorePublished threshold 1.81−2.50−2.2527.5762.7739.9889.7116.14
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–−9.01−136.6813.50−10.97−2.4812.37
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––1.031.08
Assets under construction, years of additionsOur threshold 2 years of additions0.00––––––
Effective tax ratePublished threshold 17.16 per cent–––––0.83−57.09
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––0.83−57.09
A threshold marked as ours has no published figure; it is the line we read the check against.